Circular Genomics Inc.

Early detection changes everything. In the fight against Alzheimer’s, time is our most valuable resource. New research into circular RNAs (circRNAs) is turning the dream of a simple, reliable blood test into a reality. Because of their unique stability and brain enrichment, circRNAs are helping us detect disease markers sooner than ever before and can enable: - Improved care pathways - More informed family decisions - Better long-term patient outcomes Learn how we’re scaling the future of diagnostics in our new whitepaper: na2.hubs.ly/H056GQY0

We’re pleased to welcome Henrik Zetterberg, MD, PhD to our Scientific Advisory Board. A Professor of Neurochemistry at the University of Gothenburg, University of Wisconsin–Madison, and UCL, Dr. Zetterberg is a global leader in fluid biomarkers for neurodegenerative diseases. His expertise will further advance Circular Genomics’ mission to make brain disorders measurable through innovative circRNA biomarker technology, including blood-based assays for Alzheimer’s diagnosis and risk prediction. Read the press release to learn more: na2.hubs.ly/H053MJz0

Did you know that 75% of dementia cases worldwide go undiagnosed? 🌍 For too long, getting an answer has meant jumping through hoops. Traditional diagnostics rely on a complex ""triple threat"" of testing: Cognitive Testing: Stressful exams that often catch the disease too late. Lumbar Punctures: Invasive and intimidating procedures. High-Tech Imaging: Expensive PET or MRI scans with limited availability. While these tools are effective, they aren't scalable—resulting in millions of people being left in the dark during the most critical window for treatment. At Circular Genomics, our research and technology using Circular RNA (circRNA) aims to provide insight into the underlying biology of Alzheimer's Disease, offering a clearer path toward early detection and personalized care. Learn more: na2.hubs.ly/H04tLwt0"

Alzheimer’s is the 6th leading cause of death in the U.S., and someone develops it every ~65 seconds. Early detection is critical. Identifying cognitive changes sooner gives patients the opportunity to take proactive steps to manage risk and plan for the future. At Circular Genomics, we’re developing non-invasive blood-based tests to detect Alzheimer’s earlier, helping empower patients and clinicians with actionable insights when it matters most. Learn more: na2.hubs.ly/H049Q8b0 #AlzheimersAwareness #EarlyDetection #BrainHealth #CognitiveWellness #CircularGenomics #BloodBiomarker

Studies show that lifestyle changes—regular exercise, a balanced diet, mental stimulation, and routine health check-ups—can improve cognition in older adults at risk of cognitive decline. The U.S. POINTER trial, the first large-scale RCT in the U.S., demonstrates that accessible, multidomain lifestyle interventions can protect cognitive function across diverse populations. 🔑 Why it matters: Early detection helps identify who is at risk, giving patients and caregivers the chance to take proactive steps to slow or delay cognitive decline. Everyday lifestyle choices can truly make a difference. Learn more about the study: na2.hubs.ly/H049K7S0 #BrainHealth #EarlyDetection #CognitiveWellness #AlzheimersPrevention #HealthyAging #USPOINTER

On #EmployeeAppreciationDay, we recognize the remarkable team behind Circular Genomics. Your dedication to advancing care for patients with psychiatric and neurological disorders is what drives our mission forward. Thank you for your passion, innovation, and relentless commitment to making a difference for patients and their families. #CircularGenomics #Teamwork #Innovation

Circular Genomics will be at AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases in Copenhagen 🇩🇰 📆 March 17–21, 2026 Meet our team members Jessica DeHart and Olivia Tucker and learn how circular RNA is shaping the future of blood-based biomarkers for neurodegenerative disease. 👉 Book a meeting with us at the conference: na2.hubs.ly/H041VMl0

Circular RNAs (circRNAs) are emerging as a powerful new class of biomarkers—closely tied to the biological pathways that drive Alzheimer’s disease progression, not just its symptoms. This opens the door to earlier, more precise diagnosis, helping patients, families, and clinicians gain critical time to plan, intervene, and care with greater confidence. At Circular Genomics, we’re advancing circRNA innovation to reshape how Alzheimer’s is detected and managed—because earlier insight can mean better outcomes and renewed hope. 🔗 Read our whitepaper to learn more: na2.hubs.ly/H03RpxM0 #AlzheimersResearch #Biomarkers #BrainHealth #PrecisionMedicine

Deborah Gould, diagnosed with Alzheimer’s in 2016, is living proof that a diagnosis doesn’t erase a person. She continues to speak out to break stigma and remind others to talk to people with Alzheimer’s — not about them. Her story underscores a critical need: earlier, non-invasive detection. When Alzheimer’s can be identified sooner and without invasive procedures, individuals and families gain time — for understanding, planning, and dignity. Early detection isn’t just about science. It’s about seeing people sooner, fully, and with compassion. Read Deborah's story: na2.hubs.ly/H03R0qt0 #AlzheimersAwareness #EarlyDetection #BrainHealth #PatientVoices

Circular Genomics will be at AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases in Copenhagen 🇩🇰 📆 March 17–21, 2026 Meet our team members Jessica DeHart and Olivia Tucker and learn how circular RNA is shaping the future of blood-based biomarkers for neurodegenerative disease. 👉 Book a meeting with us at the conference: na2.hubs.ly/H03LXzf0

We are proud to announce that we’ve finalized our IP licensing agreements with Washington University in St. Louis and the Max Delbrück Center, two globally recognized leaders in Alzheimer’s disease research. This milestone strengthens our scientific foundation by securing exclusive rights to key innovations advancing our circular RNA platform—accelerating development, deepening scientific validation, and creating a clearer path toward delivering non-invasive solutions for neurodegenerative diseases. Read the full press release: na2.hubs.ly/H03zFMh0

Circular Genomics is proud to support the SuperAgers: A Be Brain Powerful Event in San Diego that brings together leaders advancing brain health across the lifespan, hosted by UsAgainstAlzheimer's. Moments like this reinforce the importance of collaboration, innovation, and sustained commitment to a future where Alzheimer’s disease and related dementias can be detected earlier and addressed more effectively. We look forward to an inspiring evening with the broader brain health community.

Earlier insight in Alzheimer’s disease starts with biology. Our validated circRNA signatures detect early changes, identify fast-progressing disease, and support more efficient clinical trial enrollment—reducing screen fails and PET imaging burden. Learn more at: na2.hubs.ly/H03b6v10 #AlzheimersDisease #EarlyDetection #PatientStratification #PrecisionNeurology #Biomarkers

Terrie Montgomery’s story, featured in Being Patient, offers a powerful reminder of the human impact of Alzheimer’s disease—and the importance of being heard early in the diagnostic journey. As Terrie shares, recognizing changes early can help patients and families seek answers sooner, plan proactively, and access the right care and support at the right time. Early, biology-driven detection has the potential to shift Alzheimer’s from reactive care to informed, personalized decision-making. Read Terrie’s story: lnkd.in/gsuUdfBJ #AlzheimersDisease #PatientVoices #EarlyDetection #PrecisionNeurology #BeingPatient

Circular Genomics was recently featured in the San Diego Business Journal, highlighting our work developing circular RNA–based precision medicine tools for neurology and psychiatry. The article underscores the potential of blood-based circRNA biomarkers to enable earlier disease detection, improve patient stratification, and support more efficient therapeutic development—particularly in Alzheimer’s disease. Read the full feature in the San Diego Business Journal: na2.hubs.ly/H030l6y0 #CircularGenomics #PrecisionNeurology #AlzheimersDisease #Biotechnology #SanDiegoLifeSciences

Meet Circular Genomics at #JPM2026 Join Paul Sargeant, CEO; Nikolaos Mellios, CSO; and Sami Shihabi, CCO at the J.P. Morgan Health Care Conference to discuss how blood-based circular RNA biomarkers are advancing early detection, patient stratification, and clinical trial efficiency in Alzheimer’s disease. 🗓 January 12–15, 2026 📍 San Francisco, CA

We’re proud to be featured in ALZForum, highlighting the growing momentum behind circRNAs as a next-generation approach to AD biomarker development and their potential to complement—or reduce reliance on—traditional imaging and CSF-based methods. Read more about how circRNAs are shaping the future of Alzheimer’s disease detection and research: na2.hubs.ly/H02Z1Xs0 #AlzheimersDisease #Biomarkers #CircularRNA #PrecisionNeurology #Neurodegeneration #ClinicalTrials #BloodBasedBiomarkers #CircularGenomics

Happy New Year! ✨ The Circular Genomics team wishes you a year filled with health and happiness. Here’s to fresh starts, meaningful progress, and everything 2026 has in store.

Happy Holidays from the Circular Genomics team! We are grateful for a year of progress in advancing early detection of Alzheimer’s disease — and excited for what’s ahead in 2026.

In case you missed it… our CTAD presentation highlighted exciting early data showing how brain-derived circRNAs may offer a new path forward in Alzheimer’s detection. Here is a recap from the data presented at CTAD: Using 34 circRNAs and a single cutoff, we evaluated more than 1,200 patients from the Knight ADRC dataset and discovered: • 34 circRNAs were identified that are differentially expressed between patients with Alzheimer’s and healthy controls. • High accuracy in detecting symptomatic AD — AUC 0.945 vs. AT-negative biomarker controls • Strong ability to predict progression from asymptomatic to symptomatic AD — AUC 0.87, outperforming ptau217 alone at an AUC of 0.67 • AD-Specificity — Model showed no predictive power in non-AD dementias (LBD, FTD, Parkinson’s dementia) These findings represent an important first step as we continue to optimize and clinically validate our circRNA platform to support earlier, more accurate detection of Alzheimer’s disease.